摘要
目的 建立RP-HPLC测定血清中文拉法辛(VL及其活性代谢产物O-去甲文拉法辛(ODV的浓度。方法 血清样品碱化后采用乙醚萃取，其有机相再用盐酸反提取。采用VP-ODS柱，以甲醇-水-正丁胺-冰醋酸（54∶60∶1.5∶1.2为流动相，UV检测波长为229 nm。结果 血清文拉法辛及O-去甲文拉法辛线性范围均为31.25～500 μg·L-1，方法 回收率分别为92.3%～125.7%及109.9%～121.8%，日内RSD分别为5.52%～7.70%及1.76%～9.46%，日间RSD分别为4.59%～7.70%及 1.96%～9.59% 。结论 本法准确可靠，重现性好，适用于文拉法辛及O-去甲文拉法辛人体药动学研究中血药浓度的测定。
Abstract
OBJECTIVE To develop a RP-HPLC method for the simultaneous determination of venlafaxine (VL and its active metabolite O-desmethylvenlafaxine (ODV in serum.METHODS VL and ODV in serum were extracted by ether and were back-extracted from the organic layer into hydrochloric acid.The chromatographic separation was performed on the VP-ODS column using the mixture of methanol-water-butyl-Amine-glacial acetic acid (54∶60∶1.5∶1.2 as the mobile phase.The detection wave length was at 229 nm.RESULTS The linearity was obtained in the range of 31.25-500 μg·L-1 with the recoveries of 92.3%-125.7% and 109.9%-121.8% for ODV and VL respectively. The intraday RSDs were in the range of 5.52%-7.70% and 1.76%-9.46%， and the inter-day RSDs were in the range of 4.59%-7.70% and 1.96%-9.59% for ODV and VL， respectively.CONCLUSION This method was found to be accurate and reliable. It can be applied to the pharmacokinetic study and therapeutic drug monitoring of ODV and VL.
关键词
文拉法辛 /
O-去甲文拉法辛 /
反相高效液相色谱法 /
血药浓度
{{custom_keyword}} /
Key words
venlafaxine /
O-desmethylvenlafaxine /
RP-HPLC /
serum drug concentration
{{custom_keyword}} /
王志纲 朱雪松 马睿婷 杨丽蓉 万长亮 高波.
RP-HPLC同时测定人血清中文拉法辛及氧去甲文拉法辛的浓度[J]. 中国药学杂志, 2011, 46(1): 54-56
WNG Zhi-gng;ZHU Xue-song;M Rui-ting;YNG Li-rong;WN Chng-ling;GO o.
Simultaneous Determination of Venlafaxine and O-Desmethyl-Venlafaxine in Human Serum by RP-HPLC[J]. Chinese Pharmaceutical Journal, 2011, 46(1): 54-56
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] KAMATH J， HANDRATTA V. Desvenlafaxine succinate for major depressive disorder： a critical review of the evidence[J].Expert Rev Neurother，2008，8(12：1787-1797.
[2] SHAMS M E，ARNETH B，HIEMKE C，et al. CYP2D6 Polymorphism and clinical effect of the antidepressant Venlafaxine [J]. J Clin Pharm Ther，2006，31 (5： 493-502.
[3] SOPKO M A J R，EHRET M J，GRGAS M. Desvenlafaxine succinate for major depressive disorder [J]. Ann Pharmacother, 2008，42(10：1439-1446.
[4] LETT K F，HACKETT L P，DUSCI L J，et al. Distribution and excretion of venlafax- ine and O-desmethylvenlafaxine in human milk [J]. Br J Clin Pharmacol，1998，4(5： 349-462.
[5] REDROBE J P，BOURIN M，COLOMBEL M C，et al. Dose dependent noradrener-gic and serotonergic properties of venlafaxine in animal models indicative of antide-pressant activity[J]. Psychopharmacology，1998，13(8 ： 128-133.
[6] HERMANN M，HENDSET M，FOSAAS K. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3，*4 or*5 allele.[J]. Eur J Clin Pharmacol，2008，64(5： 483-487.
[7] SCHWEIZER E，THIELEN R J，FRAZER A. Venlafaxine ： a novel antide-pressant com-pound[J ]. Exp Opin Invest Drugs，1997，6(2：65-78.
[8] SCHWEIZER E，WEISE C，RICKELS K. Placebo-controlled trial of venlafaxine for the treatment of major depression [J ].J Clin Psychopharmacol，1991，11（16：233-236.
[9] MONTIGNY C，SILVERSTONE P H，DEBONNEL G. Venlafaxine in treatment-resistant major depression：a Canadianmulticenter，open-label trial [J].J Clin Psychopharmacol，1999，19(10 ：401-406.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(426 KB)
